Recent preclinical studies have suggested an antifibrotic role for tricyclic antidepres- 
Recent evidence has suggested that tricyclic antidepressant (TCA) use may reduce fibrogenesis in hepatic stellate cells, 8, 9 the primary cell type responsible for liver fibrosis. 10, 11 Moreover, treatment with amitriptyline, a TCA, has been shown to reduce the development of fibrosis in vivo. 9, 12 Specifically, mice treated with carbon tetrachloride (CCl4) to induce fibrosis experienced less fibrosis when treated concomitantly with amitriptyline. 9 In addition, mice pretreated with CCl4 for 5 weeks prior to treatment with amitriptyline experienced fibrosis regression. 9 Similarly, in a high fat diet model of nonalcoholic steatohepatitis (NASH), mice receiving amitriptyline experienced less fibrosis. 12 Recent data have also suggested a possible antifibrotic role of TCAs in chronic renal disease 13 and cystic fibrosis.
14 Tricyclic antidepressants have been used in clinical practice for over forty years for several indications, including depression and pain. 15 There have been no studies to determine the relationship between TCA use and fibrosis progression among patients with chronic liver disease. Thus, we performed this study in a national cohort of HCV-infected persons to delineate the impact of TCAs upon fibrosis progression, development of liver cirrhosis and incidence of hepatocellular carcinoma (HCC).
| ME THODS

| Study population
The study population consisted of persons with HCV infection in the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES). ERCHIVES is a national cohort of HCV infected and uninfected Veterans. [16] [17] [18] Briefly, we identified all HCV infected Furthermore, we excluded subjects with missing laboratory data at baseline to calculate Aspartate Aminotransferase Platelet Ratio Index (APRI) scores as well as those for whom we could not determine an APRI score at least once after use of a TCA or a selective serotonin reuptake inhibitor (SSRI). Subjects with cirrhosis at baseline, defined as APRI > 2, were also excluded from the analysis.
| Definitions
Baseline was defined as the date of first positive HCV antibody test.
Laboratory data were collected at annual intervals and the APRI score was determined as follows:
Cirrhosis was defined as an APRI score > 2 based on prior studies. 19 An average of two values closest to the start of each year (± 6 months) was used to calculate APRI. History of alcohol dependence or abuse, history of drug dependence or abuse and hypertension were determined according to ICD-9 codes (at least two outpatient or one inpatient). 22 Diagnosis of HCC was identified according to the presence of one inpatient or two outpatient ICD-9 diagnoses. 20, 23 Anaemia was defined as haemoglobin < 12 g/dL for women and <13 g/dL for men. 16 Lipid profiles included total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglyceride (TG).
| Exposures to antidepressant medications
Tricyclic antidepressant prescriptions included amoxapine, amitriptyline, desipramine, doxepin, protriptyline, nortriptyline, imipramine, and trimipramine. SSRIs included escitalopram, fluoxetine, citalopram, fluvoxamine, sertraline, paroxetine and duloxetine.
We collected the numbers of days prescribed, the dates of prescriptions ordered, number of pills per prescription and number of refills prescribed. As defined by the World Health Organization, the defined daily dose (DDD) is the average maintenance dose per day of a drug consumed by an adult. 24 The TCA DDD was then calculated for each subject using the following formula: DDD = (total amount of drug prescribed on a daily basis to a patient) ∕(amount of drug in a DDD) 24 The cumulative defined daily dose (cDDD) is defined as the sum 
| Outcomes
Our primary outcome measure was development of cirrhosis as defined by APRI > 2, and time to cirrhosis was determined to be the date of first
APRI > 2. Our secondary outcome measure was incident hepatocellular carcinoma (iHCC) based on ICD-9 codes as defined above, and time to HCC was defined as date of first ICD-9 code of HCC. Time at risk was defined from first positive HCV antibody date to the first diagnosis of cirrhosis, iHCC, last observation date in ERCHIVES, or death.
| Statistical analysis
The study population was divided into three groups according to receipt of antidepressants: those who received only TCAs, those who received only SSRIs and those who received no antidepressants. To analyse baseline characteristics between the groups, we utilized the chi-squared test for categorical and the t test for continuous variables. We plotted mean APRI score for each group to compare fibrosis progression over the study period. We generated Kaplan-Meier's curves to compare time to cirrhosis and iHCC by receipt group. We utilized Cox's proportional hazards model to determine predictors of cirrhosis. A P value < .05 was considered significant where comparisons were made. We used SAS version 9.4 (SAS Institute Inc., Cary, NC) for statistical analyses.
| Regulatory approval
The institutional review board at VA Pittsburgh Healthcare System approved the study. We obtained appropriate permissions from the data sources that provided ERCHIVES data.
| RE SULTS
We baseline HCV RNA, alcohol use or dependence, and drug use or dependence were associated with a higher risk of cirrhosis. Infection with HCV genotype 1 (vs 2-6) was associated with a lower risk of cirrhosis. SSRI use was not associated with a reduction in risk of cirrhosis (HR = 1.03, 95% CI = 0.98, 1.08). In a subset analysis, TCA use defined as cDDD ≥ 28 was not associated with a reduced risk of cirrhosis development (HR = 0.93, 95% CI = 0.83, 1.05) (Table S1 ).
Mean APRI score is shown for the three comparison groups during the study period (Figure 2 ).
Throughout the majority of the study period, subjects who re- 8, 9 which further suggests that TCAs may exert their effects independent of the aetiology of liver injury. It must be noted that the TCA doses used in vitro and in in vivo models are significantly higher than that used for the treatment of depression in patients. For example, our work has shown that nortriptyline dosed at 7000 ng/mL leads to significant reduction in expression of type 1 collagen and alpha-1 smooth muscle actin in human hepatic stellate cells. 28 In the CCl4-mouse experiment described above, mice received 180 mcg/mL of amitriptyline, a TCA that is structurally similar to nortriptyline. 9 However, the serum level seen in patients treated with nortriptyline for depression ranges between 50 and 140 ng/mL. 29 Given this preclinical data, we focused our analyses on TCA users receiving a cDDD of 180 days or greater. Interestingly, our subset analyses of TCA users receiving a cDDD of 28 days or more did not reveal a difference in cirrhosis compared to SSRI users and subjects receiving no antidepressants, suggesting that longer exposure to
| D ISCUSS I ON
TCAs may be necessary to observe an antifibrotic effect (Table S1 ).
Furthermore, when we plotted mean APRI score over time for each group, we observed that TCA users had lower mean scores throughout the study period, including at baseline. TCA users may have initiated the medication prior to the study period, which may account for the lower mean APRI scores seen at baseline and at the end of the follow-up period. However, when we controlled for baseline APRI score in our multivariate analyses, TCA use remained significantly associated with a reduction in cirrhosis development.
Tricyclic antidepressant use was not associated with a reduction in iHCC in multivariate analyses, but there were few events observed in the study, which may limit interpretation of these findings.
Of note, a nationwide population-based study by Although this study was performed on a large, wellcharacterized HCV cohort, several limitations must be recognized.
Selection bias and unaccounted-for confounders are possible, although we did control for many relevant variables including baseline APRI score, diabetes, HCV viral load at baseline and alcohol use. We utilized APRI scores rather than liver biopsy to estimate the progression of liver fibrosis. However, the use of the APRI index as a marker of liver fibrosis is well substantiated and is associated with an area under the receiver operating characteristic curve of 0.97 for identifying patients with cirrhosis. 34 The use of ICD-9 codes to identify HCC may also be interpreted as a study limitation, but this has been previously validated in the VA healthcare setting. 35 For the treatment of depression, TCAs have been widely replaced by SSRIs and this was reflected in the smaller percentage of subjects receiving TCAs during the study period. However, despite the smaller numbers, we did observe an association with TCA use and reduction in cirrhosis. Additionally, differences between the effects of distinct TCAs were not specifically assessed, nor were the effects of duration of TCA use on fibrosis progression. We also did not measure the impact of TCA use on achievement of SVR. These factors may be the focus of future studies. Moreover, additional studies are warranted to determine the impact of TCA use on fibrosis progression in other aetiologies of chronic liver disease, including NASH and alcoholic liver disease.
| CON CLUS IONS
Our results show a significant reduction in risk of cirrhosis development among TCA users in a well-characterized cohort of 
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